undamentalytics Newsletter
Sign in

Niagen Bioscience, Inc. income statement

In fiscal 2025, Niagen Bioscience, Inc. reported revenue of $129m, up 29.9% on the year before, operating income of $16.3m (a 12.6% margin) and net income of $17.4m, or $0.20 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Jan 20112011Dec 20112012Dec 20122013Dec 20132014Jan 20152015Jan 20162016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue88121015182221324659677284100129129
Cost of revenue569710101111162124262933384646
Gross profit3223581010162635414351628383
Research and development—0001134543455666
Selling and marketing13622224171821282826293639
General and administrative488587918273431362825182729
Operating income−2−8−12−4−5−2−3−16−33−31−20−27−19−681611
Interest expense0−00001000100—————
Net interest income———————————−001———
Income before tax———−4−5−3−4−17—————−591817
Income tax————0−000—————0011
Net income−2−8−12−4−5−3−3−11−33−32−20−27−17−591716
Diluted EPS−$0.12−$0.12−$0.13−$0.04−$0.15−$0.08−$0.08−$0.26−$0.61−$0.56−$0.33−$0.40−$0.24−$0.07$0.11$0.20$0.19
Diluted shares (average)16m25m32m34m35m36m37m45m55m57m61m67m70m75m78m85m85m
EBITDA−2−8−11−4−5−2−3−16−33−31−19−26−18−581711

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NAGE vs ZVRANAGE vs NAIIHRTX vs NAGEETON vs NAGE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Niagen Bioscience, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Niagen Bioscience, Inc.